Doxazocin in management of benign prostatic hyperplasia

Doxazocin in management of benign prostatic hyperplasia

A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve-ment of 90% in t...

Full description

Bibliographic Details
Main Authors: N K Mohanty, R P Arora, A K Jha, S Singh Pal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2003-01-01
Series:Indian Journal of Urology
Subjects:
α - alderneric
doxazocin
Doxacard.
Online Access:http://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=113;epage=116;aulast=Mohanty

Similar Items

Similar Items